4.075
3.44%
-0.135
Biocryst Pharmaceuticals Inc. stock is currently priced at $4.075, with a 24-hour trading volume of 364.98K.
It has seen a -3.44% decreased in the last 24 hours and a -17.21% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.27 pivot point. If it approaches the $4.03 support level, significant changes may occur.
Previous Close:
$4.21
Open:
$4.15
24h Volume:
364.98K
Market Cap:
$867.89M
Revenue:
$331.41M
Net Income/Loss:
$-226.54M
P/E Ratio:
-3.26
EPS:
-1.25
Net Cash Flow:
$-97.31M
1W Performance:
-9.67%
1M Performance:
-17.21%
6M Performance:
-25.69%
1Y Performance:
-45.73%
Biocryst Pharmaceuticals Inc. Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc.
Sector
Industry
Phone
919-859-1302
Address
4505 Emperor Boulevard, Suite 200, Durham, NC
Biocryst Pharmaceuticals Inc. Stock (BCRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
Feb-22-23 | Upgrade | Needham | Hold → Buy |
Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
Dec-10-21 | Initiated | Oppenheimer | Outperform |
Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
Mar-01-21 | Initiated | Cowen | Outperform |
Sep-29-20 | Resumed | JP Morgan | Overweight |
Jun-17-20 | Initiated | BTIG Research | Neutral |
May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-16-18 | Resumed | Piper Jaffray | Overweight |
Aug-08-18 | Resumed | JP Morgan | Overweight |
Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Dec-20-17 | Initiated | Barclays | Equal Weight |
Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Feb-09-16 | Reiterated | FBR Capital | Outperform |
Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc. Stock (BCRX) Latest News
BioCryst to Report First Quarter 2024 Financial Results on May 6
GlobeNewswire Inc.
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
GlobeNewswire Inc.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
BioCryst to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
The Motley Fool
Biocryst Pharmaceuticals Inc. Stock (BCRX) Financials Data
Biocryst Pharmaceuticals Inc. (BCRX) Revenue 2024
BCRX reported a revenue (TTM) of $331.41 million for the quarter ending December 31, 2023, a +22.37% rise year-over-year.
Biocryst Pharmaceuticals Inc. (BCRX) Net Income 2024
BCRX net income (TTM) was -$226.54 million for the quarter ending December 31, 2023, a +8.33% increase year-over-year.
Biocryst Pharmaceuticals Inc. (BCRX) Cash Flow 2024
BCRX recorded a free cash flow (TTM) of -$97.31 million for the quarter ending December 31, 2023, a +40.37% increase year-over-year.
Biocryst Pharmaceuticals Inc. (BCRX) Earnings per Share 2024
BCRX earnings per share (TTM) was -$1.18 for the quarter ending December 31, 2023, a +11.28% growth year-over-year.
About Biocryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Cap:
|
Volume (24h):